Skip to main content
Caplight Logo









Rondo Therapeutics

Rondo Therapeutics

Private
Hayward, CaliforniaHealthcare & Life Scienceshttps://www.rondotx.com/

Last Round

Series A

Mar 2, 2022

Total Funding Raised

$67M

Company Overview

Rondo Therapeutics is a biotechnology company that develops bispecific therapeutic antibodies aimed at modulating immune system activation to combat cancer, particularly in solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

immuno-oncologybispecific antibodysolid tumorsco-stimulatory therapycancer immunotherapyclinical-stage biotechbiotech drug discoveryCD28Nectin-4NGSnext-generation sequencingbiopharma R&Ddrug pipelineclinical trialsantibody engineering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Rondo Therapeutics Comparables

Compare Rondo Therapeutics with similar companies based on industry and business-model similarity.

Rondo Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Marengo Therapeutics
82%
Amgen
75%
Aktis Oncology
73%

Rondo Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 2, 2022

Key People

Founding team and executive leadership

Jennifer Isacoff McNealey

Consulting Chief Financial Officer

Executive Team

Rondo Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 1, 2025

    Advanced first oncology asset into clinical trials in 2025.

  • Mar 2, 2022

    $67M Series A round completed.

Rondo Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Rondo Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Rondo Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersHayward, California
Employee Range29
Year Founded2020
Last FundingMar 2, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?